{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-311229","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.744496+00:00","generated_at":"2026-05-16T14:04:12.456942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MiNK Therapeutics Q3 net loss $2.9M; durable remissions with agenT-797, cash runway through 2026","bullets":["Net loss $2.9M ($0.65/share) in Q3 2025 vs $1.8M ($0.46) in Q3 2024.","Cash $14.3M at quarter-end; raised $1.2M post-quarter; runway extended through 2026.","Clinical data: durable complete remissions >2 years in refractory cancers; no Grade 3+ CRS/neurotoxicity.","Launching Phase 1 GvHD study with UW-Madison, funded by NIH and philanthropy.","Appointed Dr. Terese Hammond as Head of Inflammatory and Pulmonary Diseases, Dr. Holcomb to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-311229","json":"https://secwatch.observer/filing/0001193125-25-311229.json","markdown":"https://secwatch.observer/filing/0001193125-25-311229.md","text":"https://secwatch.observer/filing/0001193125-25-311229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/0001193125-25-311229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000119312525311229/inkt-20251114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:04:12.456942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}